Chief financial officer of Becton Dickinson quits

Updated on 11 October 2012

Chief financial officer of Becton Dickinson, Mr David V Elkins, quits to start entrepreneurial venture at Round Rock Research. Mr Suketu Upadhyay, senior VP and controller, will take over as the interim CFO effective November 9, 2012

mr-david-v-elkins-evp-and-cfo-becton-dickinson-to-join-round-rock-research

Mr David V Elkins, EVP and CFO, Becton Dickinson, to join Round Rock Research

Singapore: Mr David V Elkins, executive vice president and chief financial officer of Becton, Dickinson and Company (BD) has revealed his plans of pursuing an entrepreneurial opportunity at Round Rock Research, which is a technology licensing company, serving as its CFO. He will leave BD during November following the company's release of full fiscal year 2012 results on November 7, 2012.

Mr Elkins said that, "BD is a tremendous company with outstanding people, products and prospects. While my decision to leave was difficult, this new entrepreneurial opportunity is something that makes sense for me and my family. This will give me an opportunity to work with a long-time friend at Round Rock as its CFO and help the company execute its growth strategy."

Mr Suketu Upadhyay, senior VP and controller, has been named as the interim chief financial officer, effective November 9, 2012. Prior to his current role, Mr Upadhyay served as the chief financial officer for BD's international operations. Before joining BD in 2010, he held senior-level finance positions with Johnson & Johnson and AstraZeneca.

Mr Vincent A Forlenza, chairman, CEO and president, BD, said that, "I am genuinely disappointed that we are losing David. He has been an outstanding chief financial officer and terrific partner since he joined BD in 2008, but we respect his decision to pursue the next chapter of his career elsewhere. The board and I are grateful for his contributions to BD and for his commitment to helping achieve a smooth transition. We wish him the best for the future."

Leave a Reply

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X